This drug, which is sold under the brand name Acomplia, controls appetite by targeting the endocannabinoid system, the part of the brain that regulates the body's energy and metabolism and clinical trials have shown that it can reduce weight by up to 10 percent and has important effects on glucose, cholesterol and triglyceride blood fat levels, thus reducing the risk of heart disease and diabetes considerably.
Before it becomes readily available on the NHS to others, studies must be carried out by the National Institute for Health and Clinical Excellence as to it's cost-effectiveness. Sanofi Aventis claim that the cost will be lower than the estimated £7 billion per year currently spent on dealing with weight problems.
An initial trial suggested that Acomplia also suppresses cigarette cravings and could therefore help smokers quit their habit. However, consequent tests have failed to prove the same and therefore it is being promoted solely as a weight-control measure.
